State of Wyoming’s Tvardi Therapeutics TVRD Stock Holding History

State of Wyoming’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,281	Closed	-$46.1K	–	2146
2025 Q3	$46.1K	Buy	+1,281	New	+$36.5K	0.01%	1599
2024 Q1	–	Sell	-769	Closed	-$20.6K	–	1861
2023 Q4	$20.6K	Buy	+769	New	+$31.8K	﹤0.01%	1542
2022 Q2	–	Sell	-42	Closed	-$19K	–	2185
2022 Q1	$19K	Buy	+42	New	+$17.2K	0.01%	1457

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

State of Wyoming's TVRD Position: Q4 2025 in Review

State of Wyoming sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 1,281 shares — an estimated $46.1K sold.

State of Wyoming first reported a position in TVRD in Q1 2022 and held it in 3 quarters. The position peaked at $46.1K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

State of Wyoming reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
State of Wyoming sold 1,281 Tvardi Therapeutics shares in Q4 2025, an estimated $46.1K.
State of Wyoming first reported a position in Tvardi Therapeutics in Q1 2022 and held it in 3 quarters.
State of Wyoming's Tvardi Therapeutics position peaked at $46.1K in Q3 2025.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on State of Wyoming's 13F filing for Q4 2025, filed 11 Feb 2026.